Nkarta promotes david r. shook, m.d.

South san francisco, calif., jan. 09, 2023 (globe newswire) -- nkarta, inc. (nasdaq: nktx), a clinical-stage biopharmaceutical company developing engineered natural killer (nk) cell therapies to treat cancer, today announced the promotion of david r. shook, m.d., to the role of chief medical officer. dr. shook has extensive expertise in cell therapy development and continues to lead nkarta's global clinical development and regulatory operations.
NKTX Ratings Summary
NKTX Quant Ranking